Aomo Announces China’s NMPA Acceptance of NDA for Adamgammadex
Today’s cyclodextrin is about a Sugammadex competition.
Aomo Pharma, Inc. (the US branch of Adamerck) announced recently that the China National Medical Products Administration (NMPA) accepted its new drug application (NDA) for Adamgammadex (Aom0498).
Adamgammadex (Aom0498) is the next generation of specific neuromuscular blockade antagonists and has been shown to rapidly reverse neuromuscular blockades induced by rocuronium at various depths within 3 minutes. Compared with sugammadex, adamgammadex has a lower incidence of severe adverse reactions, such as allergic reactions, neuromuscular blockade recurrence, bradycardia, and laryngospasm, while maintaining more stable efficacy.
Adamgammadex has been developed globally; it has completed an End of Phase II Meeting with the FDA, and multiregional clinical trials (MRCTs) are scheduled to be launched in the US, Europe, and Japan to bring adamgammadex (Aom0498) into the global market.
Aomo Announces China’s NMPA Acceptance of NDA for Adamgammadex – Aomo Pharma Inc.
